Randomized, Open-Label, Single Dose, 3 Period, Crossover Evaluation of the Relative Bioavailability of Two Experimental Fixed-Dose Combination Tablet Formulations of Dolutegravir 50 mg/Abacavir 600 mg/Lamivudine 300 mg Compared to Co administered Dolutegravir 50 mg and Epzicom (Abacavir 600 mg/Lamivudine 300 mg) Tablets in Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2015
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Dolutegravir; Lamivudine/abacavir
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 04 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 04 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.